A Clinical Study to Determine the Optimal Dose of WIN-1001X by Evaluating Its Efficacy and Safety in Patients With Early Parkinson's Disease: Double-blind, Randomized, Placebo-controlled, Multicenter, Phase II Study
The purpose of this study is to determine the optimal dose of WIN-1001X for its therapeutic confirmatory study by comparing and evaluating the efficacy and safety of each dose group by conducting a therapeutic exploratory study on three dose groups of WIN-1001X 400 mg, 800 mg, and 1200 mg, and placebo group in patients with early Parkinson's disease.
100 Clinical Results associated with Medi Help Line Co., Ltd.
0 Patents (Medical) associated with Medi Help Line Co., Ltd.
100 Deals associated with Medi Help Line Co., Ltd.
100 Translational Medicine associated with Medi Help Line Co., Ltd.